Mycobacterial lung disease spans everything from countries with high tuberculosis burden to a growing wave of nontuberculous mycobacteria in patients with chronic lung conditions. Molecular testing helps laboratories rapidly differentiate these organisms from a single respiratory specimen.
Article Summary
Laboratories worldwide continue to confront a dual mycobacterial burden: the persistent global threat of Mycobacterium tuberculosis Complex (MTB), and the rising incidence of Nontuberculous Mycobacteria (NTM) including Mycobacterium avium Complex (MAC) and Rapid Growing Mycobacteria (RGM) among patients with chronic lung disease. Because these organisms can produce overlapping respiratory symptoms but require very different treatment strategies and public health responses, rapid and accurate differentiation is critical. Molecular PCR-based testing can help laboratories quickly identify MTB, MAC, and RGM species from sputum or bronchoalveolar lavage (BAL) specimens, supporting faster answers and more targeted patient management.
Mycobacterial infections are a growing diagnostic challenge
Infections caused by organisms in the Mycobacterium genus range from tuberculosis, one of the deadliest infectious diseases worldwide, to an increasing number of nontuberculous mycobacterial infections in individuals with chronic lung disease, reduced immune competence due to HIV infection, cancer, chemotherapy, or transplant-related immunosuppression, or mutations in the CFTR gene or the α-1-antitrypsin gene. Because clinical presentations often overlap and treatment regimens differ significantly by organism, rapid and specific identification is essential for both patient management and public health response.
Below is an overview of the three major mycobacterial groups laboratories are asked to differentiate, their clinical relevance, and current testing approaches.
Mycobacterium tuberculosis Complex (MTB)
Tuberculosis remains one of the deadliest infectious diseases worldwide. MTB Complex organisms include M. africanum, M. bovis, M. canettii, M. caprae, M. microti, M. mungi, M. orygis, M. pinnipedii, M. suricattae, and M. tuberculosis.¹
While primarily a respiratory infection, MTB can affect any organ. Clinical manifestations typically include:
- Chronic cough
- Hemoptysis (coughing up blood)
- Fever
- Night sweats
- Weight loss
Molecular diagnosis relies on sputum or BAL sampling, which remains a significant challenge for many patients, particularly children and HIV-positive individuals, who may be unable to undergo invasive collection procedures or produce an adequate specimen. This limitation is driving innovative diagnostic approaches, including the prospective use of non-invasive tongue swab sampling.²,³
Mycobacterium avium Complex (MAC)
All Mycobacterium species other than the MTB Complex and M. leprae are collectively classified as nontuberculous mycobacteria (NTM)⁴,⁵. Among these, Mycobacterium avium Complex (MAC) is the most common cause of respiratory NTM infection in humans, comprised of M. avium, M. intracellulare, M. colombiense, M. arosiense, M. vulneris, M. bouchedurhonense, M. timonense, M. marseillense, M. paraintracellulare, and M. lepraemurium.⁶
MAC organisms are waterborne, opportunistic pathogens found in natural waters and soils, and are known to proliferate and persist in plumbing systems within households and hospitals.⁴,⁷ MAC poses particular risk to individuals with:
- Reduced immune competence (HIV infection, cancer, chemotherapy, or transplant-related immunosuppression)
- Pre-existing lung conditions
- Mutations in the CFTR gene or the α-1-antitrypsin gene⁴
Unlike TB, NTM infections are not typically transmitted person-to-person, rather they are acquired from environmental sources such as soil and water. Rapidly differentiating NTM from MTB is vital for appropriate treatment selection and public health management, since NTM cases do not trigger the same contact-tracing and reporting response as active TB.
Rapid Growing Mycobacteria (RGM): M. chelonae, M. abscessus Group, M. fortuitum Complex
More than 75 recognized RGM species can cause severe respiratory infections as well as skin and soft tissue infections. Common sources include contaminated water and surgical devices.⁸
Among RGM species, Mycobacterium abscessus is routinely identified as multidrug-resistant and is considered one of the most difficult mycobacterial infections to treat. Because M. abscessus requires a specialized, aggressive antibiotic strategy compared to other mycobacteria, rapid molecular identification is crucial to initiating appropriate therapy without delay.⁹
How are mycobacterial infections detected?
Because MTB, MAC, and RGM can present with overlapping respiratory symptoms yet require distinct clinical and public health responses, molecular testing that can rapidly differentiate between them offers a significant advantage over traditional methods alone.
| Diagnostic Method | Differentiates MTB / MAC / RGM | Turnaround | Typical Specimen |
| Culture | Yes, but slow | Days to weeks | Sputum, BAL |
| Microscopy (AFB smear) | No (detects acid-fast bacilli, not species) | Hours | Sputum, BAL |
| Chest imaging (X-ray / HRCT) | No | Same day | N/A |
| Molecular PCR | Yes | Hours | Sputum, BAL |
The advantages of molecular testing for mycobacterial differentiation
Traditional detection methods such as culture, microscopy, and imaging remain important tools, but culture in particular can require weeks for definitive species identification, delaying treatment decisions.
Molecular PCR-based testing offers several advantages:
- Rapid time to results within just hours instead of the days to weeks required for culture
- High analytical sensitivity and specificity for species-level differentiation
- Faster differentiation between MTB and NTM, supporting appropriate treatment and public health decisions
- Reduced reliance on sequential confirmatory testing
Because MTB, MAC, and RGM require substantially different management. From public health contact-tracing for active TB to specialized antibiotic regimens for M. abscessus, rapid molecular differentiation directly supports faster, more appropriate clinical decision-making.
Why differentiating MTB from NTM matters for public health
Tuberculosis is a reportable disease with well-established public health surveillance and contact-tracing protocols. NTM infections, including MAC and RGM, are managed differently. They are not person-to-person transmissible and do not require the same public health response, but they do require distinct, often prolonged treatment regimens.
Because clinical presentation alone cannot reliably distinguish these organisms, rapid and accurate laboratory differentiation is essential for:
- Correctly triggering (or ruling out) public health contact-tracing protocols for active TB
- Selecting an appropriate antimicrobial regimen, particularly for multidrug-resistant organisms like M. abscessus
- Avoiding unnecessary isolation precautions or treatment delays for NTM-positive, TB-negative patients
BioGX Sample-Ready™ solutions for mycobacterial testing
BioGX offers Sample-Ready™ lyophilized reagents validated for use with the ABI QuantStudio™ Series, Bio-Rad CFX Series, and BD MAX™ system, supporting differentiation across the mycobacterial groups discussed above:
- Mycobacterium tuberculosis Complex (MTB)
- Mycobacterium avium Complex (MAC)
- Mycobacterium spp.
- Mycobacterium chelonae
- Mycobacterium abscessus group
- Mycobacterium fortuitum complex
Speed of identification supports the specific, timely management of suspected mycobacterial infections, helping laboratories move from a broad clinical suspicion to an actionable, organism-specific result. A full breakdown of targets, part numbers, and platform compatibility is available on the BioGX Respiratory Multiplexes page, along with the MTBC product flyer.
Note: BioGX real-time PCR reagents referenced above are manufactured and packaged as open system reagents (OSR) for use with open system platforms and must be validated by the user. Available as Research Use Only: Not for use in diagnostic procedures.
Choosing the right Product
Laboratories can select the Sample-Ready™ format that best matches their testing needs:
REF 450-054-Series: for laboratories prioritizing rapid differentiation of MTB, MAC, and Mycobacterium spp. from sputum or BAL specimens.
REF 450-055-Series: for laboratories needing to identify Rapid Growing Mycobacteria, including Mycobacterium chelonae, the Mycobacterium abscessus group and the Mycobacterium fortuitum complex from respiratory or wound-associated specimens.
Both formats are compatible with widely used real-time PCR platforms like ABI QuantStudio™ Series, Bio-Rad CFX Series, and BD MAX™ allowing laboratories to implement mycobacterial differentiation testing on existing instrumentation.
Looking ahead
As TB continues to represent a major global infectious disease burden and NTM infections rise among patients with chronic lung disease, laboratories remain essential partners in rapid, accurate mycobacterial differentiation. Molecular testing can help laboratories deliver faster, more specific answers that guide both individual patient treatment and broader public health response.
Frequently Asked Questions
What is the difference between MTB and NTM?
MTB (Mycobacterium tuberculosis Complex) causes tuberculosis and is person-to-person transmissible, triggering public health contact-tracing protocols. NTM (nontuberculous mycobacteria, including MAC and RGM) are environmentally acquired from soil, water, or plumbing systems and are not typically transmitted between people.
What are the symptoms of MTB infection?
Common symptoms include chronic cough, hemoptysis, fever, night sweats, and weight loss.
Who is at higher risk for MAC infection?
Individuals with reduced immune competence (HIV, cancer, chemotherapy, transplant-related immunosuppression), pre-existing lung conditions, or mutations in the CFTR or α-1-antitrypsin genes.
What makes Mycobacterium abscessus difficult to treat?
M. abscessus is routinely multidrug-resistant and requires a specialized, aggressive antibiotic strategy distinct from other mycobacteria, making rapid identification critical.
Which platforms are BioGX Sample-Ready™ mycobacterial reagents validated for?
ABI QuantStudio™ Series, Bio-Rad CFX Series, and BD MAX™ system. See platform compatibility details for part-number-specific guidance.
Can MTB, MAC, and RGM be differentiated using molecular testing?
Yes. BioGX offers targeted Sample-Ready™ reagent sets: REF 450-054-Series for MTB, MAC, and Mycobacterium spp., and REF 450-055-Series for M. chelonae, M. abscessus group, and M. fortuitum complex.
References
- Bespiatykh, D., Bespyatykh, J., Mokrousov, I., & Shitikov, E. (2021). A comprehensive map of Mycobacterium tuberculosis complex regions of difference. Msphere, 6(4), 10-1128.
- Wang, Y., Ma, Z., Liu, Z., Dong, X., Shu, W., Wei, M., & Pang, Y. (2025). Tongue swab-based molecular diagnostics for pulmonary tuberculosis and drug resistance in adults: A prospective multicenter diagnostic accuracy study. Journal of Infection, 106517.
- Andama, A., Whitman, G. R., Crowder, R., Reza, T. F., Jaganath, D., Mulondo, J., & Cattamanchi, A. (2022). Accuracy of tongue swab testing using Xpert MTB-RIF Ultra for tuberculosis diagnosis. Journal of Clinical Microbiology, 60(7), e00421-22.
- Falkinham, III, J.O. (2009). Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. Journal of Applied Microbiology, 107: 356-367.
- Van Ingen, J., Turenne, C. Y., Tortoli, E., Wallace Jr, R. J., & Brown-Elliott, B. A. (2018). A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review. International Journal of Systematic and Evolutionary Microbiology, 68(11), 3666-3677.
- Keen, E. C., Choi, J., Wallace, M. A., Azar, M., Mejia-Chew, C. R., Mehta, S. B., … & Dantas, G. (2021). Comparative genomics of Mycobacterium avium complex reveals signatures of environment-specific adaptation and community acquisition. Msystems, 6(5), 10-1128.
- Matos, S., Portugal, I., & Perdigão, J. (2025). The Mycobacterium avium Complex: Genomics, Disease, and Beyond. Microorganisms, 13(10), 2329.
- Brown-Elliott, B. A., & Philley, J. V. (2017). Rapidly growing mycobacteria. Tuberculosis and nontuberculous mycobacterial infections, 703-723.
- Nessar, R., Cambau, E., Reyrat, J. M., Murray, A., & Gicquel, B. (2012). Mycobacterium abscessus: a new antibiotic nightmare. Journal of Antimicrobial Chemotherapy, 67(4), 810-818.
Disclaimer: Information in this blog is provided for educational and informational purposes only. It is not intended to provide diagnostic or treatment recommendations. Readers are encouraged to consult appropriate scientific and public health sources.
